



## Credit for Learning

### • LEUKAEMIA •

#### THE QUESTIONS

##### 1. In acute leukaemia, patients may have:

- |  |   |   |
|--|---|---|
| a) A raised white cell count.....                                  | T | F |
| b) Thrombocytopenia.....   | T | F |
| c) Evidence of renal impairment .....                              | T | F |
| d) A decreased number of platelets in the cerebrospinal fluid..... | T | F |
| e) Abdominal distension .....                                      | T | F |

##### 2. The aetiology of acute leukaemias is associated with:

- |  |   |   |
|--|---|---|
| a) Human T-cell lymphotropic virus .....     | T | F |
| b) Cytotoxic drugs.....                      | T | F |
| c) Genetic factors .....                     | T | F |
| d) Exposure to radiation.....                | T | F |
| e) A much lower risk in identical twins..... | T | F |

##### 3. Acute myeloid leukaemia (AML):

- |  |   |   |
|--|---|---|
| a) Is the most common leukaemia in adults .....                          | T | F |
| b) Of the AML M3 type is the most curable.....                           | T | F |
| c) Has a remission rate of 70 to 80 per cent.....                        | T | F |
| d) Is treated with etoposide and methotrexate in induction regimens..... | T | F |

- |  |   |   |
|--|---|---|
| e) Has a relapse rate of 55 per cent despite complete remission after induction therapy..... | T | F |
|--|---|---|

##### 4. Acute lymphoblastic leukaemia (ALL):

- |  |   |   |
|--|---|---|
| a) Is predominantly a disease of childhood.....  | T | F |
| b) Is potentially curable .....  | T | F |
| c) Has a leukaemia-free survival rate of 65 per cent in adults with the disease .....                    | T | F |
| d) Is usually treated with drugs such as vincristine and anthracyclines.....                             | T | F |
| e) Is usually treated for long-term maintenance, with a regimen including weekly oral methotrexate ..... | T | F |

##### 5. Good prognostic markers for ALL include:

- |  |   |   |
|--|---|---|
| a) Patient is male.....                                  | T | F |
| b) A low white cell count.....                           | T | F |
| c) Patient has B-ALL .....                               | T | F |
| d) The presence of CNS disease at presentation .....     | T | F |
| e) Achievement of remission in less than four weeks..... | T | F |

Questions continue overleaf



## Credit for Learning

### LEUKAEMIA

#### 6. In chronic myeloid leukaemia (CML):

- |  |   |   |
|--|---|---|
| a) There are three classic phases termed chronic, accelerated and blast phases .....                   | T | F |
| b) 50 per cent of patients have a genetic translocation forming the Philadelphia (Ph) chromosome ..... | T | F |
| c) The presence of the bcr-abl transcript on the Ph chromosome is diagnostic of CML .....              | T | F |
| d) The median age of onset is 20 to 30 years .....   | T | F |
| e) The majority of patients will transform to the blast phase and will die of their disease .....      | T | F |

#### 7. In considering treatments for CML:

- |   |   |   |
|---|---|---|
| a) Interferon- $\alpha$ provides a significant survival advantage compared with hydroxyurea and busulphan ..... | T | F |
| b) Chlorambucil is the drug of choice .....   | T | F |
| c) Busulphan 0.5mg/kg/day is given for 10 days .....  | T | F |
| d) Imatinib is used in the chronic phase of Ph-positive disease .....   | T | F |
| e) Hydroxyurea achieves a complete haematological response in 30 per cent of patients .....                     | T | F |

#### 8. Interferon- $\alpha$ therapy:

- |  |   |   |
|--|---|---|
| a) Induces a complete haematological remission in up to 80 per cent of patients with CML ..... | T | F |
| b) Has been shown to prolong survival in patients with CML by 10 to 12 years .....             | T | F |
| c) Can produce a variety of dose-dependent side effects .....                                  | T | F |
| d) Is associated with a median time to respond of three months .....                           | T | F |

- |  |   |   |
|--|---|---|
| e) Induces a complete cytogenetic response in 10 to 30 per cent of patients with CML ..... | T | F |
|--|---|---|

#### 9. In the treatment of CLL:

- |   |   |   |
|---|---|---|
| a) Therapy is started immediately in the early phase .....  | T | F |
| b) Chlorambucil is regarded as the standard first-line treatment .....  | T | F |
| c) Monoclonal antibodies, such as rituximab and alemtuzumab, are being studied currently and have shown high response rates ..... | T | F |
| d) Fludarabine has been shown to produce high response rates in the Binet B and C stages .....                                    | T | F |
| e) The aim is to put the disease back into remission and control any symptoms .....   | T | F |

#### 10. In the diagnosis and pathology of CLL:

- |   |   |   |
|---|---|---|
| a) Approximately 50 per cent of patients have a genetic abnormality .....   | T | F |
| b) The majority of patients are symptomatic when diagnosed .....  | T | F |
| c) The lymphoid cells affected are CD5+ cells found in lymphoid follicles and peripheral blood .....  | T | F |
| d) Patients have a 90 per cent increased risk of developing a secondary cancer .....  | T | F |
| e) The patient has a raised white cell count (WCC greater than $5 \times 10^9/L$ ), with the cells appearing as small lymphocytes with round nuclei, clumped chromatin and scanty cytoplasm ..... | T | F |